Composition, form of production and packaging
Concentrate for solution for infusion 1 ml
potassium chloride 150 mg
Auxiliary substances: hydrochloric acid 0.1M to pH 3-4, water d / and up to 1 ml.
100 ml - bottles (1) - packs of cardboard.
100 ml - bottles (1) - packs cardboard (35) - cardboard boxes.
200 ml - bottles (1) - packs of cardboard.
200 ml - bottles (1) - packs cardboard (28) - cardboard boxes.
Concentrate for solution for infusion 1 ml
potassium chloride 30 mg
Auxiliary substances: hydrochloric acid 0.1 M to pH 3-4, water d / and up to 1 ml.
100 ml - bottles (1) - packs of cardboard.
100 ml - bottles (1) - packs cardboard (35) - cardboard boxes.
200 ml - bottles (1) - packs of cardboard.
200 ml - bottles (1) - packs cardboard (28) - cardboard boxes.
Concentrate for solution for infusion 1 ml
potassium chloride 40 mg
Auxiliary substances: hydrochloric acid 0.1 M to pH 3-4, water d / and up to 1 ml.
100 ml - bottles (1) - packs of cardboard.
100 ml - bottles (1) - packs cardboard (35) - cardboard boxes.
200 ml - bottles (1) - packs of cardboard.
200 ml - bottles (1) - packs cardboard (28) - cardboard boxes.
Concentrate for solution for infusion 1 ml
potassium chloride 75 mg
Auxiliary substances: hydrochloric acid 0.1 M to pH 3-4, water d / and up to 1 ml.
100 ml - bottles (1) - packs of cardboard.
100 ml - bottles (1) - packs cardboard (35) - cardboard boxes.
200 ml - bottles (1) - packs of cardboard.
200 ml - bottles (1) - packs cardboard (28) - cardboard boxes.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2011.
PHARMACHOLOGIC EFFECT
Potassium preparation, restores water-electrolyte balance. Has a negative chrono- and batmotropic effect, in high doses - negative foreign and dromotropic, as well as moderate diuretic effect. In small doses, the potassium drug dilates the coronary vessels, in large - narrows. Participates in the process of carrying out nerve impulses.With intravenous administration, adrenaline is increased by the adrenal glands.
Activates many cytoplasmic enzymes, participates in maintaining intracellular osmotic pressure, in protein-synthetic reactions and transport of amino acids. Improves the contraction of skeletal muscles in muscular dystrophy, myasthenia gravis. Increase in potassium concentration reduces the risk of toxic effects of cardiac glycosides.
INDICATIONS
Hypokalemia (including diabetes mellitus, prolonged diarrhea and / or vomiting, therapy with antihypertensive drugs, certain diuretics, glucocorticosteroids), treatment and prevention of glycoside intoxication, paroxysmal tachycardia, prevention and treatment of ectopic arrhythmias in patients with myocardial infarction (acute) .
DOSING MODE
In / in struyno, if necessary in / in drip in combination with 5% dextrose solution.
With hypokalemia with a violation of the heart rhythm - 1-1.5 g 4-5 times a day; after restoring the heart rhythm, the dose is reduced. With glycosidic intoxication - 2-3 g / day, in severe cases - up to 5 g. For arresting attacks of paroxysmal tachycardia on the first day - 8-12 g, followed by a decrease to 3-6 g.
In severe intoxications, requiring rapid elimination of pathological phenomena, as well as persistent vomiting, the drug is administered iv. Apply 4% solution of the drug in 40% glucose solution. 50 ml of the solution is diluted (for the preparation of an isotonic solution) with water for injection 10 times (up to 500 ml) and droplets 20-30 drops per minute are introduced). It is also possible to inject intravenously at 2.5 g in 500 ml of a 0.9% solution of sodium chloride or a 5% solution of dextrose.
For the prevention and treatment of ectopic arrhythmias in myocardial infarction - a polarizing mixture: potassium chloride solution in a 5% -10% solution of dextrose (add short-acting insulin at the rate of 1 unit for 3-4 g of dry dextrose).
SIDE EFFECT
From the nervous system: paresthesia, muscle weakness, confusion.
From the cardiovascular system: lowering blood pressure, arrhythmia, heart block, heart failure .
Other: hyperkalemia, allergic reactions.
CONTRAINDICATIONS
Hyperkalemia, complete atrioventricular block, adrenal insufficiency, chronic renal failure, concomitant therapy with potassium-sparing diuretics, metabolic disorders (acidosis, hypovolemia with hyponatremia), age under 18 years (efficacy and safety not established).
PREGNANCY AND LACTATION
If necessary, use in pregnancy should be compared with the expected benefit for the mother and the potential risk to the fetus.
During the period of breastfeeding, the question of its cessation should be resolved.
APPLICATION FOR FUNCTIONS OF THE LIVER
Contraindicated in chronic renal failure.
APPLICATION FOR CHILDREN
The safety and effectiveness of potassium chloride in children under 18 years of age have not been established.
SPECIAL INSTRUCTIONS
During the treatment it is necessary to control the content of potassium ions in the blood serum, electrocardiogram, in the treatment of hypokalemia - control of the acid-base state.
Safety and effectiveness of potassium chloride in children have not been established.
A diet with a high sodium content increases the excretion of potassium from the body.
It should be borne in mind that hyperkalemia, leading to death, can develop rapidly and proceed asymptomatically.
OVERDOSE
Symptoms: hyperkalemia (muscle hypotension, paresthesia of the limbs, slowing of atrioventricular conduction, arrhythmias, cardiac arrest). Early clinical signs of hyperkalemia usually appear at a potassium concentration in the serum of more than 6 meq / l: tapering of the T wave, disappearance of the U wave (if present in the previous cardiograms), a decrease in the ST segment, prolongation of the QT interval, expansion of the QRS complex. More severe symptoms of hyperkalemia - muscle paralysis and cardiac arrest - develop at a potassium concentration of 9-10 meq / L.
Treatment: inside or in / in - 0.9% solution of sodium chloride; in / in - 300-500 ml of a 5% solution of dextrose (with 10-20 units of insulin per liter); if necessary, hemodialysis and peritoneal dialysis.
DRUG INTERACTION
Pharmaceutically compatible with solutions of cardiac glycosides (improves their tolerability).
Strengthens the negative dromo- and batmotropic effect of antiarrhythmic drugs.
Beta-adrenoblockers, cyclosporine, potassium-sparing diuretics, heparin, angiotensin-converting enzyme inhibitors, non-steroidal anti-inflammatory drugs may increase the risk of hyperkalemia.
TERMS OF RELEASE FROM PHARMACY
The drug is released by prescription.
TERMS AND CONDITIONS OF STORAGE
At a temperature of 15 to 25 В° C. Keep out of the reach of children.
Shelf life - 1 year. After the expiry date, the drug should not be used.
